FI119733B - Menetelmiä sellaisten rekombinantti -IL4-vasta-aineiden valmistamiseksi jotka ovat käyttökelpoisia IL-4-välitteisten häiriötilojen hoidossa - Google Patents

Menetelmiä sellaisten rekombinantti -IL4-vasta-aineiden valmistamiseksi jotka ovat käyttökelpoisia IL-4-välitteisten häiriötilojen hoidossa Download PDF

Info

Publication number: FI119733B
Authority: FI; Finland
Prior art keywords: seq; human; antibody; sequence; ser
Prior art date: 1993-09-07

Application number

FI961083A

Other languages

English (en)

Finnish (fi)

Swedish (sv)

Other versions

FI961083A0 (fi

FI961083L (fi

Inventor

Mitchell Stuart Gross

Stephen Dudley Holmes

Daniel R Sylvester

Original Assignee

Smithkline Beecham Plc

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-09-07

Filing date

1996-03-07

Publication date

2009-02-27

1996-03-07 Application filed by Smithkline Beecham Plc, Smithkline Beecham Corp filed Critical Smithkline Beecham Plc

1996-03-07 Publication of FI961083A0 publication Critical patent/FI961083A0/fi

1996-05-06 Publication of FI961083L publication Critical patent/FI961083L/fi

2009-02-27 Application granted granted Critical

2009-02-27 Publication of FI119733B publication Critical patent/FI119733B/fi

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/247—IL-4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hematology (AREA)
Cell Biology (AREA)
Food Science & Technology (AREA)
Analytical Chemistry (AREA)
Pulmonology (AREA)
Microbiology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Physics & Mathematics (AREA)
Biotechnology (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

FI961083A 1993-09-07 1996-03-07 Menetelmiä sellaisten rekombinantti -IL4-vasta-aineiden valmistamiseksi jotka ovat käyttökelpoisia IL-4-välitteisten häiriötilojen hoidossa FI119733B (fi)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US11736693A	1993-09-07	1993-09-07
US11736693		1993-09-07
US13678393A	1993-10-14	1993-10-14
US13678393		1993-10-14
US9410308		1994-09-07
PCT/US1994/010308 WO1995007301A1 (en)	1993-09-07	1994-09-07	Recombinant il4 antibodies useful in treatment of il4 mediated disorders

Publications (3)

Publication Number	Publication Date
FI961083A0 FI961083A0 (fi)	1996-03-07
FI961083L FI961083L (fi)	1996-05-06
FI119733B true FI119733B (fi)	2009-02-27

Family

ID=26815208

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI961083A FI119733B (fi)	1993-09-07	1996-03-07	Menetelmiä sellaisten rekombinantti -IL4-vasta-aineiden valmistamiseksi jotka ovat käyttökelpoisia IL-4-välitteisten häiriötilojen hoidossa

Country Status (21)

Country	Link
EP (1)	EP0730609B1 (zh)
JP (4)	JPH09502708A (zh)
KR (1)	KR100362340B1 (zh)
CN (2)	CN1105728C (zh)
AP (1)	AP583A (zh)
AT (1)	ATE286510T1 (zh)
AU (1)	AU695726B2 (zh)
BG (1)	BG63549B1 (zh)
BR (1)	BR9407575A (zh)
CA (1)	CA2171336C (zh)
CZ (1)	CZ295928B6 (zh)
DE (1)	DE69434223T2 (zh)
ES (1)	ES2236693T3 (zh)
FI (1)	FI119733B (zh)
HU (1)	HU222041B1 (zh)
NO (1)	NO960956L (zh)
NZ (1)	NZ274338A (zh)
PL (1)	PL180125B1 (zh)
SK (1)	SK285556B6 (zh)
UA (1)	UA48940C2 (zh)
WO (1)	WO1995007301A1 (zh)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7588766B1 (en)	2000-05-26	2009-09-15	Elan Pharma International Limited	Treatment of amyloidogenic disease
US6761888B1 (en)	2000-05-26	2004-07-13	Neuralab Limited	Passive immunization treatment of Alzheimer's disease
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en)	1998-04-07	2010-09-07	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en)	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en)	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
PE20020574A1 (es)	2000-12-06	2002-07-02	Wyeth Corp	Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en)	2000-12-06	2010-04-20	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize β-amyloid peptide
US6768004B2 (en) *	2001-01-11	2004-07-27	Mueller Sybille	Nucleotide sequences encoding variable regions of heavy and light chains of monoclonal antibody 1F7, an anti-idiotypic antibody reactive with anti-HIV antibodies
MY139983A (en)	2002-03-12	2009-11-30	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
TWI374893B (en) *	2003-05-30	2012-10-21	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
EP3653641A1 (en)	2004-02-19	2020-05-20	Genentech, Inc.	Cdr-repaired antibodies
PE20060560A1 (es)	2004-08-03	2006-06-27	Novartis Ag	Anticuerpos de interleucina-4 humana
EP1838348B1 (en)	2004-12-15	2013-06-26	Janssen Alzheimer Immunotherapy	Humanized amyloid beta antibodies for use in improving cognition
ES2396555T3 (es)	2004-12-15	2013-02-22	Janssen Alzheimer Immunotherapy	Anticuerpos que reconocen péptido beta amiloide
EP2004691A1 (en) *	2006-03-22	2008-12-24	Apogenix GmbH	Antibody specific for human il-4 for the treament of cancer
US8784810B2 (en)	2006-04-18	2014-07-22	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases
ES2371287T3 (es)	2006-06-21	2011-12-29	Apogenix Gmbh	Expresión diferencial de la citocina en cáncer humano.
US8003097B2 (en)	2007-04-18	2011-08-23	Janssen Alzheimer Immunotherapy	Treatment of cerebral amyloid angiopathy
JP4971872B2 (ja)	2007-05-23	2012-07-11	株式会社トプコン	眼底観察装置及びそれを制御するプログラム
SI2182983T1 (sl)	2007-07-27	2014-09-30	Janssen Alzheimer Immunotherapy	Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
EP2050764A1 (en)	2007-10-15	2009-04-22	sanofi-aventis	Novel polyvalent bispecific antibody format and uses thereof
JO3076B1 (ar)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
JP5324839B2 (ja)	2008-06-19	2013-10-23	株式会社トプコン	光画像計測装置
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
CN102294024B (zh) *	2011-01-17	2013-03-13	广东现代农业集团研究院有限公司	一种多肽疫苗及其制备方法
CN107614762B (zh) *	2015-02-24	2022-08-05	台湾地区“中央研究院”	一种由噬菌体表达的单链变异片段抗体库
CN112625129B (zh) *	2020-11-26	2022-05-20	江苏荃信生物医药股份有限公司	一种抗人白介素23及包含其的试剂盒及其检测方法
CN112646040B (zh) *	2020-12-31	2022-03-25	中元汇吉生物技术股份有限公司	特异性结合人IgG4的蛋白及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5041381A (en) *	1986-07-03	1991-08-20	Schering Corporation	Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
JP2646007B2 (ja) *	1988-01-30	1997-08-25	財団法人化学及血清療法研究所	抗ｈｉｖ抗体可変領域をコードする遺伝子断片およびこれらを用いて発現された抗ｈｉｖキメラ抗体ならびにその製法
EP0365209A3 (en) *	1988-10-17	1990-07-25	Becton, Dickinson and Company	Anti-leu 3a amino acid sequence
IL162181A (en) *	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
JPH07119238B2 (ja) *	1989-12-18	1995-12-20	小野薬品工業株式会社	ヒトインターロイキン―４に対するモノクローナル抗体および該抗体の利用方法
DE69026627T2 (de) *	1989-12-20	1996-08-22	Schering Corp., Kenilworth, N.J.	Antikörperantagonisten gegen humanes interleukin-4
JPH04141095A (ja) *	1990-10-02	1992-05-14	Chemo Sero Therapeut Res Inst	組換え抗ｈｉｖ改変抗体および改変抗体の調製方法
AU684041B2 (en) *	1992-02-19	1997-12-04	Schering Corporation	Cloning and expression of humanized monoclonal antibodies against human interleukin-4
JPH06269663A (ja) *	1993-03-17	1994-09-27	Toyobo Co Ltd	Ｃｄ４陽性細胞捕集材
DE60025364T2 (de) *	1999-07-30	2006-08-03	Battelle Memorial Institute, Richland	Glaskeramisches verbindungsmaterial und verbindungsverfahren

1994
- 1994-09-07 ES ES94929191T patent/ES2236693T3/es not_active Expired - Lifetime
- 1994-09-07 AT AT94929191T patent/ATE286510T1/de not_active IP Right Cessation
- 1994-09-07 DE DE69434223T patent/DE69434223T2/de not_active Expired - Lifetime
- 1994-09-07 NZ NZ274338A patent/NZ274338A/en not_active IP Right Cessation
- 1994-09-07 BR BR9407575A patent/BR9407575A/pt not_active Application Discontinuation
- 1994-09-07 CN CN94193929A patent/CN1105728C/zh not_active Expired - Fee Related
- 1994-09-07 UA UA96041300A patent/UA48940C2/uk unknown
- 1994-09-07 AU AU78340/94A patent/AU695726B2/en not_active Ceased
- 1994-09-07 JP JP7508835A patent/JPH09502708A/ja active Pending
- 1994-09-07 KR KR1019960701168A patent/KR100362340B1/ko not_active Expired - Fee Related
- 1994-09-07 AP APAP/P/1996/000782A patent/AP583A/en active
- 1994-09-07 CN CNA031043178A patent/CN1473854A/zh active Pending
- 1994-09-07 WO PCT/US1994/010308 patent/WO1995007301A1/en active IP Right Grant
- 1994-09-07 EP EP94929191A patent/EP0730609B1/en not_active Expired - Lifetime
- 1994-09-07 HU HU9600616A patent/HU222041B1/hu not_active IP Right Cessation
- 1994-09-07 CA CA2171336A patent/CA2171336C/en not_active Expired - Fee Related
- 1994-09-07 CZ CZ1996698A patent/CZ295928B6/cs not_active IP Right Cessation
- 1994-09-07 SK SK333-96A patent/SK285556B6/sk not_active IP Right Cessation
- 1994-09-07 PL PL94313491A patent/PL180125B1/pl not_active IP Right Cessation
1996
- 1996-03-07 FI FI961083A patent/FI119733B/fi not_active IP Right Cessation
- 1996-03-07 NO NO960956A patent/NO960956L/no unknown
- 1996-04-05 BG BG100480A patent/BG63549B1/bg unknown
2006
- 2006-09-07 JP JP2006243117A patent/JP2007045831A/ja active Pending
- 2006-09-07 JP JP2006243103A patent/JP2006333870A/ja active Pending
2009
- 2009-06-02 JP JP2009133207A patent/JP2009191077A/ja active Pending

Also Published As

Publication number	Publication date
EP0730609B1 (en)	2005-01-05
AP9600782A0 (en)	1996-04-30
WO1995007301A1 (en)	1995-03-16
DE69434223D1 (de)	2005-02-10
PL313491A1 (en)	1996-07-08
ATE286510T1 (de)	2005-01-15
EP0730609A1 (en)	1996-09-11
BG63549B1 (bg)	2002-04-30
AU695726B2 (en)	1998-08-20
BG100480A (bg)	1996-12-31
NO960956D0 (no)	1996-03-07
UA48940C2 (uk)	2002-09-16
CN1133599A (zh)	1996-10-16
CN1105728C (zh)	2003-04-16
AU7834094A (en)	1995-03-27
DE69434223T2 (de)	2005-12-22
CN1473854A (zh)	2004-02-11
AP583A (en)	1997-04-14
SK33396A3 (en)	1996-10-02
CZ69896A3 (en)	1996-10-16
CA2171336A1 (en)	1995-03-16
ES2236693T3 (es)	2005-07-16
PL180125B1 (pl)	2000-12-29
NO960956L (no)	1996-05-06
JP2006333870A (ja)	2006-12-14
SK285556B6 (sk)	2007-03-01
CZ295928B6 (cs)	2005-12-14
JP2009191077A (ja)	2009-08-27
JPH09502708A (ja)	1997-03-18
JP2007045831A (ja)	2007-02-22
HU9600616D0 (en)	1996-05-28
BR9407575A (pt)	1996-07-16
EP0730609A4 (en)	2000-05-10
HU222041B1 (hu)	2003-04-28
NZ274338A (en)	1998-02-26
FI961083A0 (fi)	1996-03-07
FI961083L (fi)	1996-05-06
HUT75833A (en)	1997-05-28
CA2171336C (en)	2011-06-21
KR100362340B1 (ko)	2003-02-26

Publication	Publication Date	Title
FI119733B (fi)	2009-02-27	Menetelmiä sellaisten rekombinantti -IL4-vasta-aineiden valmistamiseksi jotka ovat käyttökelpoisia IL-4-välitteisten häiriötilojen hoidossa
EP1299421B1 (en)	2009-03-25	Antibodies to human mcp-1
EP1163271B1 (en)	2008-07-23	Recombinant il-18 antibodies and their use
US7807793B2 (en)	2010-10-05	Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
RU2162711C2 (ru)	2001-02-10	Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4
WO1995001997A1 (en)	1995-01-19	RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
AU2001283903A1 (en)	2002-04-11	Antibodies to human MCP-1
HU228159B1 (en)	2013-01-28	Antibodies to human il-1beta
JP2013091636A (ja)	2013-05-16	Ｉｌ−５により媒介される疾病の治療に有用な組み換えｉｌ−５アンタゴニスト
US5928904A (en)	1999-07-27	DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5914110A (en)	1999-06-22	Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
JP2001523083A (ja)	2001-11-20	Ｉｌ−５により媒介される疾病の治療に有用な組み換えｉｌ−５アンタゴニスト
RO116809B1 (ro)	2001-06-29	Anticorp recombinant, monoclonal, compozitie farmaceutica si metoda de tratament cu aceasta
MXPA01009514A (en)	2002-06-05	Recombinant il-18 antagonists useful in treatment of il-18 mediated disorders

Legal Events

Date	Code	Title	Description
2009-02-27	FG	Patent granted	Ref document number: 119733 Country of ref document: FI
2013-04-10	MM	Patent lapsed

Date

Code

Title

Description

2009-02-27

Patent granted

Ref document number: 119733

Country of ref document: FI

2013-04-10

Patent lapsed